Washington, DC (April 2, 2019) – The Healthcare Supply Chain Association (HSCA) Board of Directors is
pleased to announce that it has named leading national healthcare expert Khatereh Calleja as President
and CEO of the Healthcare Supply Chain Association, effective April 29, 2019. Calleja joins HSCA from
AdvaMed, the world’s largest association representing manufacturers of medical devices, diagnostic
products, and medical information systems, where she served as Senior Vice President of Technology
and Regulatory Affairs.
Click here for the full release.Lear More
Dear Chairman Pallone and Ranking Member Walden,
I am writing to you on behalf of the Healthcare Supply Chain Association (HSCA) to thank you for your continued leadership on the important issue of drug pricing and the pressing need to stop anti-competitive abuses that keep drug prices high. HSCA shares your belief that a competitive marketplace will lower the price of generic drugs and help ensure that price spikes for critical generic drugs do not jeopardize patient access to care.
Click here to read the full letter.Lear More
Washington, DC (January, 2019) – The Healthcare Supply Chain Association (HSCA) today announced that GNYHA Ventures, Inc. President Lee Perlman will serve as Chair of HSCA’s Board of Directors, replacing HealthTrust CEO Ed Jones, who will serve as Immediate Past Chair. GNYHA Ventures, the business arm of Greater New York Hospital Association, includes the group purchasing organization Acurity, Inc.
Comments of the Healthcare Supply Chain Association to FDA on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Food and Drug Administration (FDA) on the causes of critical prescription drug shortages and potential solutions.
HSCA, its member GPOs, and our member healthcare providers are committed to preventing and mitigating prescription drug shortages and ensuring continued patient access to essential medications. We applaud the FDA for having taken steps to address drug shortages, including forming a drug shortage task force. As FDA has previously noted, drug shortages are a complex issue caused by quality problems, manufacturing delays, and capacity difficulties and one that requires a multi-stakeholder solution. A 2018 study conducted by Alex Brill at Global Matrix Advisors echoed FDA’s findings on drug shortages and also emphasized the need for a multi-stakeholder solution. In pursuit of finding a multi-stakeholder solution, HSCA participates in a drug shortage working group composed of leading healthcare provider organizations – including hospitals, health-system pharmacists, physicians, GPOs, and other supply chain stakeholders – to develop policy proposals to help prevent and address drug shortages in a comprehensive manner. A number of those policy ideas are reflected in HSCA’s recommendations below.Lear More